Loading clinical trials...
Loading clinical trials...
Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Bay Area Cancer Research Group
Concord, California, United States
East Bay Medical Oncology/Hematology Associates
Concord, California, United States
Southwest Cancer Care
Escondido, California, United States
Kaiser Permanente Medical Center
Hayward, California, United States
Southwest Cancer Care
Murrieta, California, United States
Kaiser Permanente Medical Center
Oakland, California, United States
Southwest Cancer Care
Poway, California, United States
Kaiser Permanente Medical Center
Sacramento, California, United States
Kaiser Permanente Medical Center
San Francisco, California, United States
Kaiser Permanente Medical Center
San Jose, California, United States
Start Date
August 1, 2004
Primary Completion Date
May 1, 2009
Completion Date
May 1, 2009
Last Updated
May 31, 2012
100
ACTUAL participants
TLK286
DRUG
carboplatin
DRUG
paclitaxel
DRUG
Lead Sponsor
Telik
NCT06667908
NCT04165798
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06875310